$AKTX
Akari Therapeutics Plc

2015 Q2 Form 10-Q Financial Statement

#000114420415029638 Filed on May 12, 2015

View on sec.gov

Income Statement

Concept 2015 Q2 2015 Q1 2014 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.314M $99.68K $1.083M
YoY Change 66.33% -90.8%
% of Gross Profit
Research & Development $142.0K $1.555M $800.0K
YoY Change -90.78% 94.37%
% of Gross Profit
Depreciation & Amortization $10.00K $764.00 $0.00
YoY Change
% of Gross Profit
Operating Expenses $1.456M $1.655M $1.883M
YoY Change -37.51% -12.13%
Operating Profit -$1.456M -$2.342M -$1.883M
YoY Change -37.51% 24.38%
Interest Expense -$20.00K $4.556K $140.0K
YoY Change -87.5% -96.75%
% of Operating Profit
Other Income/Expense, Net -$215.0K -$42.16K $143.0K
YoY Change -312.87% -129.48%
Pretax Income -$1.671M -$2.877M -$1.740M
YoY Change -25.03% 65.34%
Income Tax $0.00 -$560.0K $0.00
% Of Pretax Income
Net Earnings -$1.671M -$2.317M -$1.740M
YoY Change -25.03% 33.16%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.679K -$2.353K -$35.17K
COMMON SHARES
Basic Shares Outstanding 55.64M shares 722.3M shares
Diluted Shares Outstanding 722.3M shares

Balance Sheet

Concept 2015 Q2 2015 Q1 2014 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.720M $4.020M
YoY Change
Cash & Equivalents $2.718M $1.329M $13.83M
Short-Term Investments
Other Short-Term Assets $140.0K $140.0K
YoY Change
Inventory
Prepaid Expenses
Receivables $60.00K $120.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.920M $4.273M
YoY Change
LONG-TERM ASSETS
Property, Plant & Equipment $40.00K $44.00K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $40.00K $44.00K
YoY Change
TOTAL ASSETS
Total Short-Term Assets $2.920M $4.273M
Total Long-Term Assets $40.00K $44.00K
Total Assets $2.960M $4.317M
YoY Change
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $630.0K $300.0K
YoY Change
Accrued Expenses
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $960.0K $910.0K
YoY Change
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $43.00K $38.00K
YoY Change
Total Long-Term Liabilities $43.00K $812.0K
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $960.0K $910.0K
Total Long-Term Liabilities $43.00K $812.0K
Total Liabilities $1.003M $1.722M
YoY Change
SHAREHOLDERS EQUITY
Retained Earnings -$32.51M
YoY Change
Common Stock $35.10M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $970.0K $2.595M
YoY Change
Total Liabilities & Shareholders Equity $2.960M $4.317M
YoY Change

Cashflow Statement

Concept 2015 Q2 2015 Q1 2014 Q1
OPERATING ACTIVITIES
Net Income -$1.671M -$2.317M -$1.740M
YoY Change -25.03% 33.16%
Depreciation, Depletion And Amortization $10.00K $764.00 $0.00
YoY Change
Cash From Operating Activities -$1.510M -$1.988M -$2.048M
YoY Change -35.19% -2.91%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change -100.0%
Cash From Investing Activities $0.00 $0.00 $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $8.219M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 $0.00 $8.219M
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -1.510M -$1.988M -$2.048M
Cash From Investing Activities 0.000 $0.00 $0.00
Cash From Financing Activities 0.000 $0.00 $8.219M
Net Change In Cash -1.510M -$1.988M $6.171M
YoY Change -38.87% -132.22%
FREE CASH FLOW
Cash From Operating Activities -$1.510M -$1.988M -$2.048M
Capital Expenditures $0.00 $0.00
Free Cash Flow -$1.988M -$2.048M
YoY Change -2.91%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q1 dei Document Period End Date
DocumentPeriodEndDate
2015-03-31
CY2015Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2015Q1 dei Trading Symbol
TradingSymbol
CLTX
CY2015Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
55636283 shares
CY2015Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4016000 USD
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
6216000 USD
CY2015Q1 cltx Accounts Receivable And Prepaid Expenses Net Current
AccountsReceivableAndPrepaidExpensesNetCurrent
115000 USD
CY2014Q4 cltx Accounts Receivable And Prepaid Expenses Net Current
AccountsReceivableAndPrepaidExpensesNetCurrent
73000 USD
CY2015Q1 us-gaap Assets Current
AssetsCurrent
4273000 USD
CY2014Q4 us-gaap Assets Current
AssetsCurrent
6431000 USD
CY2015Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
44000 USD
CY2014Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
49000 USD
CY2015Q1 us-gaap Assets
Assets
4317000 USD
CY2014Q4 us-gaap Assets
Assets
6480000 USD
CY2015Q1 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
296000 USD
CY2014Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1003000 USD
CY2015Q1 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
614000 USD
CY2014Q4 us-gaap Accounts Payable Other Current
AccountsPayableOtherCurrent
356000 USD
CY2014Q4 us-gaap Common Stock Value
CommonStockValue
927000 USD
CY2015Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
34175000 USD
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
34116000 USD
CY2015Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32507000 USD
CY2014Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-30190000 USD
CY2015Q1 us-gaap Stockholders Equity
StockholdersEquity
2595000 USD
CY2014Q4 us-gaap Stockholders Equity
StockholdersEquity
4853000 USD
CY2015Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4317000 USD
CY2014Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6480000 USD
CY2015Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2015
CY2015Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2015Q1 dei Entity Registrant Name
EntityRegistrantName
Celsus Therapeutics Plc.
CY2015Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001541157
CY2015Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2015Q1 dei Document Type
DocumentType
10-Q
CY2015Q1 dei Amendment Flag
AmendmentFlag
false
CY2015Q1 us-gaap Liabilities Current
LiabilitiesCurrent
910000 USD
CY2014Q4 cltx Liability Related To Stock Options And Warrants
LiabilityRelatedToStockOptionsAndWarrants
235000 USD
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1883000 USD
CY2015Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2015Q1 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
812000 USD
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2014Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
268000 USD
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1359000 USD
CY2015Q1 cltx Liability Related To Stock Options And Warrants
LiabilityRelatedToStockOptionsAndWarrants
774000 USD
CY2015Q1 us-gaap Common Stock Value
CommonStockValue
927000 USD
CY2015Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2015Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
5000000000 shares
CY2015Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55636283 shares
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
55636283 shares
CY2015Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55636283 shares
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
55636283 shares
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
800000 USD
CY2015Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1551000 USD
CY2014Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1083000 USD
CY2015Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
791000 USD
CY2015Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2342000 USD
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
143000 USD
CY2015Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-535000 USD
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-1740000 USD
CY2015Q1 us-gaap Net Income Loss
NetIncomeLoss
-2317000 USD
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2903227 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2903227 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2903227 shares
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1515727 shares
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.42
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.42
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
1.42
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
1.36
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y9M18D
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2015Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
5814000 USD
CY2014 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
8219000 USD
CY2014 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
412000 USD
CY2015Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
59000 USD
CY2014 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
56000 USD
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-9648000 USD
CY2015Q1 cltx Share Based Compensation Arrangement By Share Based Payment Award Options And Warrants Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndWarrantsOutstandingNumber
631970 shares
CY2014 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.60
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
195000 USD
CY2015Q1 us-gaap Share Based Compensation
ShareBasedCompensation
59000 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
8219000 USD
CY2015Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
2.00
CY2014Q1 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
0.60
CY2014Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
981000 USD
CY2007Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1365000 shares
CY2015Q1 us-gaap Stock Issued During Period Value Share Based Compensation Gross
StockIssuedDuringPeriodValueShareBasedCompensationGross
59000 USD
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
15333300 shares
CY2014 cltx Warrants Granted Value
WarrantsGrantedValue
234000 USD
CY2015Q1 cltx Warrants Granted Value
WarrantsGrantedValue
774000 USD
CY2015Q1 cltx Warrants Expired During Period
WarrantsExpiredDuringPeriod
562500 shares
CY2015Q1 cltx Common Stock Capital Shares Reserved For Future Issuance Under Most Favoured Nations Terms
CommonStockCapitalSharesReservedForFutureIssuanceUnderMostFavouredNationsTerms
5659717 shares
CY2015Q1 cltx Common Stock Capital Shares Reserved For Future Issuance Under Price Protection
CommonStockCapitalSharesReservedForFutureIssuanceUnderPriceProtection
5089544 shares
CY2015Q1 cltx Warrants Stock Reserved For Future Issuance Under Price Protection
WarrantsStockReservedForFutureIssuanceUnderPriceProtection
729450 shares
CY2015Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1929824 shares
CY2015Q1 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
2308000 USD
CY2013Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
787000 USD
CY2014 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
552000 USD
CY2015Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-539000 USD
CY2014Q4 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
235000 USD
CY2015Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis With Unobservable Inputs
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisWithUnobservableInputs
774000 USD
CY2014Q1 us-gaap Depreciation
Depreciation
0 USD
CY2015Q1 us-gaap Depreciation
Depreciation
5000 USD
CY2014Q1 cltx Increase Decrease In Values Of Deferred Shares And Liability Related To Stock Options And Warrants
IncreaseDecreaseInValuesOfDeferredSharesAndLiabilityRelatedToStockOptionsAndWarrants
151000 USD
CY2015Q1 cltx Increase Decrease In Values Of Deferred Shares And Liability Related To Stock Options And Warrants
IncreaseDecreaseInValuesOfDeferredSharesAndLiabilityRelatedToStockOptionsAndWarrants
-539000 USD
CY2014Q1 cltx Increase Decrease In Accounts Receivables And Prepaid Expense
IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense
160000 USD
CY2015Q1 cltx Increase Decrease In Accounts Receivables And Prepaid Expense
IncreaseDecreaseInAccountsReceivablesAndPrepaidExpense
42000 USD
CY2014Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
192000 USD
CY2015Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
-707000 USD
CY2014Q1 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
-384000 USD
CY2015Q1 us-gaap Increase Decrease In Other Accounts Payable
IncreaseDecreaseInOtherAccountsPayable
258000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2048000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2200000 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
0 USD
CY2014Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
8219000 USD
CY2015Q1 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
0 USD
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
8219000 USD
CY2015Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
6171000 USD
CY2015Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2200000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7657000 USD
CY2014Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13828000 USD
CY2015Q1 us-gaap Other Restricted Assets Current
OtherRestrictedAssetsCurrent
142000 USD
CY2014Q4 us-gaap Other Restricted Assets Current
OtherRestrictedAssetsCurrent
142000 USD
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
49472951 shares
CY2015Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
55636283 shares
CY2014Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0 USD
CY2015Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5000 USD
CY2015Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
38000 USD
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000 USD
CY2015Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2015Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
0 shares
CY2015Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
0
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
218000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
297000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
313000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
330000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
225000 USD
CY2015Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1383000 USD
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
56000 USD
CY2015Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.57
CY2014Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2015Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-560000 USD
CY2014Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1740000 USD
CY2015Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-2877000 USD
CY2015Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
252000 USD
CY2014Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2015Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0 pure
CY2014Q1 cltx Fair Value Assumptions Forfeiture Rate
FairValueAssumptionsForfeitureRate
0 pure
CY2015Q1 cltx Fair Value Assumptions Forfeiture Rate
FairValueAssumptionsForfeitureRate
0 pure

Files In Submission

Name View Source Status
0001144204-15-029638-index-headers.html Edgar Link pending
0001144204-15-029638-index.html Edgar Link pending
0001144204-15-029638.txt Edgar Link pending
0001144204-15-029638-xbrl.zip Edgar Link pending
cltx-20150331.xml Edgar Link completed
cltx-20150331.xsd Edgar Link pending
cltx-20150331_cal.xml Edgar Link unprocessable
cltx-20150331_def.xml Edgar Link unprocessable
cltx-20150331_lab.xml Edgar Link unprocessable
cltx-20150331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v409890_10q.htm Edgar Link pending
v409890_ex31-1.htm Edgar Link pending
v409890_ex31-2.htm Edgar Link pending
v409890_ex32-1.htm Edgar Link pending